StockNews.com downgraded shares of TG Therapeutics ( NASDAQ:TGTX – Free Report ) from a hold rating to a sell rating in a research report report published on Wednesday morning. Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an overweight rating and issued a $24.00 price objective on shares of TG Therapeutics in a research note on Monday, April 17th. HC Wainwright reiterated a buy rating and set a $28.00 target price (up previously from $24.

https://www.dailypolitical.com/2023/07/15/tg-therapeutics-nasdaqtgtx-lowered-to-sell-at-stocknews-com.html

#dailypolitical